Articles
-
2 weeks ago |
healio.com | Andrew Rhoades |Harold Bays
Key takeaways:Some obesity drugs in development have different mechanisms of action and may cost less than currently available drugs. However, educating clinicians about all these drugs may present a challenge. Obesity medications in development could improve accessibility and affordability, according to a presenter at Obesity Medicine 2025.
-
1 month ago |
healio.com | Andrew Rhoades |Harold Bays
NATIONAL HARBOR, Md. —In this video at Obesity Medicine 2025, Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC, FNLA, discusses highlights from his talk on anti-obesity medications in the pipeline. There is an “unbelievable number of anti-obesity drugs in development,” including GLP-1 receptor agonists with other incretins and appetite suppressants, Bays, chief science officer and president-elect of the Obesity Medicine Association, told Healio.
-
Feb 28, 2025 |
uscjournal.com | Harold Bays |Naveed Sattar |Gurleen Kaur |Saman Nematollahi
Average (ratings) Abstract With the dawn of advanced technological and digital resources, medical education has changed. Learners are now able to learn, share, and communicate medical knowledge through online discussion forums, blogs, videos, podcasts, infographics, virtual communities, social media platforms, and collaborative author groups. Navigating these digital education modalities can be challenging, with each platform presenting unique challenges and opportunities.
-
Nov 27, 2024 |
radcliffecvrm.com | Harold Bays |Lydia Alexander |Harriette Van Spall
Video Published: Views: 36 Likes: 0 Average (ratings) AHA Conference 2024 - Outcomes of SELECT show that semaglutide treatment in obese or overweight patients with prior history of coronary artery bypass graft (CABG) surgery reduces the risk of cardiovascular events. Dr Subodh Verma (University of Toronto, Toronto, CA) joins us onsite at AHA Conference to discuss the findings from SELECT (NCT03574597).
-
Nov 18, 2024 |
radcliffecvrm.com | Harriette Van Spall |Harold Bays |Mikhail Kosiborod
AHA Conference 2024 — Semaglutide shows increased benefits in CKD patients based on their cardiovascular status and risk profile. Dr Harriette Van Spall (McMaster University, CA) sits down with Dr Katherine Tuttle (University of Washington, US) to discuss the effects of semaglutide in patients with chronic kidney disease (CKD). The FLOW trial (NCT03819153) is designed to assess the effect of semaglutide as compared to placebo in patients with chronic kidney disease and type 2 diabetes.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →